Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
House Oversight Committee Chair James Comer is demanding answers from pharmacy benefit managers CVS Caremark, Optum Rx, and Express Scripts over a suspicious spike in audits targeting independent pharmacies. The timing? Right after those pharmacies publicly backed PBM reform legislation. Comer wants documents, communications, and briefings to determine whether the audits were punitive — including one tied to a 99-cent medication that required hundreds of staff hours to address.
House Oversight Committee Chair James Comer (R-KY) is turning up the heat on the pharmacy benefit manager industry's "Big Three" — CVS Caremark, Optum Rx, and Express Scripts. He's sent formal letters demanding documents and communications to investigate whether these PBMs launched retaliatory audits against independent pharmacies that publicly supported the Pharmacists Fight Back in FEHB Plans Act (H.R. 6610).
The concern: shortly after the committee's July markup of that bill, multiple independent pharmacies reportedly received an unusual surge of audit notices — some with compliance deadlines set before the pharmacies even received them. One audit was tied to a medication costing just 99 cents, yet required hundreds of hours of staff time to address.
Comer, a longtime PBM reform advocate since 2021, is requesting audit process details, pharmacy selection data, and specific records for pharmacies in Kentucky, Florida, and Mississippi.
Key Takeaways:
Why it matters: Independent pharmacies are a critical access point for patients, especially in rural areas. If PBMs can use audits to discourage reform advocacy, it threatens both pharmacy sustainability and the broader push for a more transparent, competitive drug pricing system.
